Premium
Frontispiece: The Glycoproteomics–MS for Studying Glycosylation in Cardiac Hypertrophy and Heart Failure
Author(s) -
Yang Shuang,
Chatterjee Subroto,
Cipollo John
Publication year - 2018
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201870042
Subject(s) - glycosylation , heart failure , biomarker , cardiology , medicine , glycoproteomics , muscle hypertrophy , cardiac hypertrophy , chatterjee , left ventricular hypertrophy , glycan , glycoprotein , chemistry , biochemistry , blood pressure , bengali , linguistics , philosophy
Aberrant protein glycosylation is associated with the occurrence of cardiac hypertrophy. Heart arterial blood contains a biomarker (brain naturetic protein: BNP) with normal glycosylation, but substantially upregulated when cardiac hypertrophy occurs. The BNP is decorated by O‐glycans. The cover design stands for (1) HCM heart diseases reviewed in the paper; (2) BNP is the gold standard biomarker for HCM; (3) BNP has a remarkable O‐glycosylation after HCM occurs; (4) Background shows the glycan biosynthesis. This is reported by Shuang Yang, Subroto Chatterjee, John Cipollo in article number 1700075 .